CD274 and non-small cell lung carcinoma: In the Checkmate 026 trial, which compared nivolumab, an ICI, with standard of care (SOC), there was no improvement in progression-free survival (PFS) for NSCLC patients with a PD-L1 expression of less than or equal to 5% [95].